SHP465 FDA Approval Status
SHP465 is a long-acting, triple-bead, mixed amphetamine salts formulation in development as a potential once-daily treatment for Attention-Deficit/Hyperactivity Disorder (ADHD).
Development Timeline for SHP465
|Jan 19, 2017||U.S. FDA Acknowledges Receipt of Shire’s New Drug Application for SHP465 for ADHD|
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.